Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.270
+0.300 (30.93%)
At close: Apr 21, 2025, 4:00 PM
1.160
-0.110 (-8.66%)
After-hours: Apr 21, 2025, 7:36 PM EDT

Company Description

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally.

The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform.

It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.

The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms.

The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses.

The company also provides medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.

Evogene Ltd.
Evogene logo
Country Israel
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 117
CEO Ofer Haviv

Contact Details

Address:
13 Gad Feinstein Street, Park Rehovot
Rehovot, 7638517
Israel
Phone 972 8 931 1900
Website evogene.com

Stock Details

Ticker Symbol EVGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574565
CUSIP Number M4119S104
ISIN Number IL0011050551
SIC Code 2870

Key Executives

Name Position
Amit Noam Capt. res. Chief Executive Officer of Lavie Bio Ltd.
Dr. Dan Jacob Gelvan Ph.D. Chief Executive Officer of Ag Plenus Ltd.
Yoash Zohar Chief Executive Officer of Casterra Ag Ltd.
Dr. Elran Hillel Haber M.B.A., Ph.D. Chief Executive Officer of Biomica Ltd
Ofer Haviv CPA Chief Executive Officer, President and Director
Yaron Eldad Chief Financial Officer
Liat Foigel Wejgman Vice President of Human Resources
Russ Putland Executive Vice President Commercial and General Manager USA

Latest SEC Filings

Date Type Title
Apr 21, 2025 6-K Report of foreign issuer
Apr 2, 2025 EFFECT Notice of Effectiveness
Mar 28, 2025 POS AM Post-Effective amendments for registration statement
Mar 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2025 20-F Annual and transition report of foreign private issuers
Mar 6, 2025 424B3 Prospectus
Mar 6, 2025 6-K Report of foreign issuer
Mar 6, 2025 6-K Report of foreign issuer
Feb 12, 2025 424B3 Prospectus
Feb 12, 2025 6-K Report of foreign issuer